Atropine

Eyenovia’s phase 3 CHAPERONE study evaluating low-dose atropine delivered via the company’s Optejet dispenser is not meeting its primary endpoint of a less than 0.50 D progression in visual acuity over 3 years, according to a press release.

Data published in July in JAMA Ophthalmology showed that 0.01% atropine drops safely curbed myopia progression in children with intermittent exotropia and myopia.

Treatment with low-level red light therapy and atropine led to similar increases in superficial retinal vascular density in premyopic children, whereas only red light therapy affected deep retinal vascular density, according to research.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Benjamin H. Ticho, MD, discusses the growing prevalence of myopia worldwide and the role that low-dose atropine may play in treating it.

Eyenovia has announced the reacquisition of development and commercialization rights to MicroPine, an investigational 8 µL ophthalmic atropine spray being evaluated for pediatric progressive myopia.

Research into effective treatments for myopic progression expands beyond contact lenses and involves atropine, red light therapy and spectacle lenses, as Healio has reported throughout 2023.

Healio’s top items from this year’s American Academy of Ophthalmology meeting included pearls for navigating secondary dry eye disease as well as data for low-dose atropine as a myopia treatment in children aged 3 to 17 years.

SAN FRANCISCO — A low-dose, preservative-free formulation of atropine is effective in slowing myopia progression in children aged 3 to 17 years, according to phase 3 data presented here.

NEW ORLEANS — Objectively measured accommodative amplitude increased throughout the day in children using low-dose atropine for myopia management, according a study presented at Academy ’23.

According to a 2016 analysis of 145 studies including 2.1 million participants, myopia will affect nearly 50% of the global population by 2050.